AnaptysBio (NASDAQ:ANAB) Stock Rating Reaffirmed by HC Wainwright

AnaptysBio (NASDAQ:ANAB)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports. They currently have a $55.00 target price on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 48.65% from the stock’s previous close.

A number of other research firms have also recently commented on ANAB. Wedbush reaffirmed an “outperform” rating and issued a $34.00 price target on shares of AnaptysBio in a report on Friday, May 10th. SVB Leerink started coverage on shares of AnaptysBio in a research report on Tuesday, April 16th. They issued an “outperform” rating and a $47.00 target price for the company. JPMorgan Chase & Co. upped their price target on shares of AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Finally, Leerink Partnrs reiterated an “outperform” rating on shares of AnaptysBio in a report on Tuesday, April 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $52.56.

AnaptysBio Trading Up 11.0 %

NASDAQ:ANAB traded up $3.67 during trading hours on Wednesday, hitting $37.00. 1,273,843 shares of the company were exchanged, compared to its average volume of 331,096. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of -6.09 and a beta of -0.25. AnaptysBio has a one year low of $13.36 and a one year high of $41.31. The company has a fifty day simple moving average of $28.97 and a 200 day simple moving average of $25.43.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.82). The business had revenue of $10.97 million during the quarter, compared to the consensus estimate of $25.85 million. AnaptysBio had a negative return on equity of 161.40% and a negative net margin of 711.17%. Equities research analysts predict that AnaptysBio will post -6.32 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction that occurred on Thursday, July 18th. The shares were sold at an average price of $35.00, for a total transaction of $52,500.00. Following the sale, the insider now owns 11,618 shares in the company, valued at $406,630. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, insider Paul F. Lizzul sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, July 18th. The shares were sold at an average price of $35.00, for a total value of $52,500.00. Following the sale, the insider now owns 11,618 shares in the company, valued at $406,630. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Hollings Renton sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $30.64, for a total transaction of $306,400.00. Following the completion of the sale, the director now owns 1,950 shares in the company, valued at approximately $59,748. The disclosure for this sale can be found here. Insiders have sold a total of 16,900 shares of company stock worth $484,824 over the last 90 days. 33.70% of the stock is currently owned by insiders.

Institutional Trading of AnaptysBio

Several institutional investors and hedge funds have recently modified their holdings of ANAB. SG Americas Securities LLC bought a new stake in shares of AnaptysBio during the 4th quarter valued at $126,000. Trexquant Investment LP increased its holdings in AnaptysBio by 107.6% in the 4th quarter. Trexquant Investment LP now owns 21,832 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 11,318 shares during the last quarter. Quest Partners LLC bought a new stake in AnaptysBio in the 4th quarter valued at $119,000. Franklin Resources Inc. increased its holdings in AnaptysBio by 22.7% in the 4th quarter. Franklin Resources Inc. now owns 405,115 shares of the biotechnology company’s stock valued at $8,678,000 after acquiring an additional 75,025 shares during the last quarter. Finally, First Light Asset Management LLC increased its holdings in AnaptysBio by 56.4% in the 4th quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock valued at $26,500,000 after acquiring an additional 446,372 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.